/Companies

Arkea Bio

Charlestown, US · Founded 2021 · 4 known investors

Find your way into Arkea Bio

Sign up to see every warm intro you have to Arkea Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Arkea Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

ArkeaBio develops a methane-reducing vaccine for cattle that lowers agricultural emissions without disrupting farm operations, targeting livestock producers to enable low-carbon dairy and beef production. The vaccine activates a natural immune response in ruminants and integrates seamlessly with existing farming practices.

Founders & leadership

FWFrank Wooten
Frank WootenChief Executive OfficerCEO of ArkeaBio, which develops a methane-reducing vaccine for cattle to lower agricultural emissions.
ZSZach Serber
Zach SerberChief Technology OfficerChief Technology Officer at ArkeaBio
CSColin South
Colin SouthChief Business OfficerColin South is Chief Business Officer at ArkeaBio. He has held executive and technology leadership roles across food, life sciences, and energy sectors, with background in engineering and science combined with business strategy and commercialization expertise.
ZS
Zachariah SerberNamed on SEC filing
GS
Ginja SilvaNamed on SEC filing
MD
Matthew DunnNamed on SEC filing

Board

WM
Wayne McNeeBoard director
CR
Chris RivestBoard director

Investors · 4

Funding

SEC filings, press & company announcements

$48.5M disclosed across 3 of 7 rounds · 2022–2026

▶$15MraisedOct 2026 · 2 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Frank WootenExecutive Officer, Director
  • Zachariah SerberExecutive Officer
  • Chris RivestDirector
  • Wayne McNeeDirector
Offering amount
$33M
Amount sold
$15M
First sale
Sep 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7MraisedOct 2025 · 2 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Frank WootenExecutive Officer, Director
  • Wayne McNeeDirector
  • Chris RivestExecutive Officer, Director
  • Zachariah SerberExecutive Officer, Director
Offering amount
$12M
Amount sold
$7M
First sale
Sep 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedDec 2023 · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ginja SilvaExecutive Officer
  • Chris RivestExecutive Officer, Director
  • Matthew DunnExecutive Officer
  • Zachariah SerberDirector
  • Colin SouthExecutive Officer, Director
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Frequently asked questions

What does Arkea Bio do?
ArkeaBio develops a methane-reducing vaccine for cattle that lowers agricultural emissions without disrupting farm operations, targeting livestock producers to enable low-carbon dairy and beef production. The vaccine activates a natural immune response in ruminants and integrates seamlessly with existing farming practices.
Who are Arkea Bio's investors?
Arkea Bio's investors include Breakthrough Energy Ventures, NYA Ventures, Rabo Corporate Venturing, AgriZeroNZ.
How much funding has Arkea Bio raised?
Arkea Bio has disclosed $48.5M raised across 3 of its 7 known rounds.
Where is Arkea Bio headquartered?
Arkea Bio is headquartered in Charlestown, US.